Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.74 - $46.00
Previous CloseN/A
Volume41.45K
Average Volume (3M)923.94K
Market Cap
$2.78B
Enterprise Value$1.99B
Total Cash (Recent Filing)$549.63M
Total Debt (Recent Filing)$8.68M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 05, 2025EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding77,105,800
10 Day Avg. Volume1,169,732
30 Day Avg. Volume923,939
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue265.66
Enterprise Value/Gross Profit-3.02K
Enterprise Value/Ebitda-6.85
Forecast
1Y Price Target
$55.40Price Target Upside47.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe enrollment completion of the Phase 3 X-TOLE2 study marks a key milestone for azetukalner.
Market PotentialAzetukalner has shown signs of improving depression and anhedonia in two Phase 2 studies, which is encouraging on the drug’s potential to help with epilepsy patients’ mood and could be a key driver of its achieving significant commercial success.
Product DifferentiationAzetukalner's strong and durable efficacy, novel mechanism, convenient dosing, and positive mood impact are seen as key differentiators among anti-seizure medications.
Bears Say
CompetitionPotential competition from BioHaven Pharmaceuticals with its Kv7 channel modulator, BHV-7000, which is expected to readout results in focal onset epilepsy.
Regulatory TimelinesXENE will refine timelines for trial results once the trial's last patient has been randomized.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $46.00 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $2.78B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Nov 05, 2025 which is in 82 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Aug 11, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$0.083.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.14.
How many shares outstanding does Xenon have?
Xenon has 77,105,800 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went up 5.512%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.40 (47.07% Upside)
$55.40 (47.07% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 613.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.4 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.91%
12-Months-Change
Fundamentals
Return on Equity
-37.65%
Trailing 12-Months
Asset Growth
-23.72%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc. (XENE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve the lives of patients with neurological disorders. The company primarily operates in the pharmaceutical and biotechnology sectors, leveraging its proprietary ion channel neurology platform to advance its pipeline of novel therapeutics. Xenon's core products include a range of investigational drugs targeting various neurological conditions, including epilepsy and pain disorders.
XENE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicated significant progress across Xenon's pipeline, particularly with azetukalner in epilepsy and MDD. Financially, the company is well-positioned to support ongoing developments. Despite a slight delay in the X-TOLE2 study and a negative primary endpoint in the MDD study, the overall sentiment remains positive due to consistent progress and strong financial backing.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$55.40
▲(47.07% Upside)
Technical Analysis
Merus
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
MoonLake Immunotherapeutics
―
Ownership Overview
0.14% Insiders
29.60% Mutual Funds
0.62% Other Institutional Investors
63.40% Public Companies and
Individual Investors